Viral Vectors and Plasmid DNA Manufacturing Market Size, Share, Growth Report 2032

The global viral vectors and plasmid DNA manufacturing market size was worth around USD 5.49 billion in 2023 and is predicted to grow to around USD 22.29 billion by 2032 with a compound annual growth rate (CAGR) of roughly 16.85% between 2024 and 2032.

Request Free Sample

The report covers a forecast and an analysis of the viral vectors and plasmid DNA manufacturing market on a global and regional level. The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD Billion). The study includes drivers and restraints for the viral vectors and plasmid DNA manufacturing market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the viral vectors and plasmid DNA manufacturing market on a global level.

Request Free Sample

Viral Vectors and Plasmid DNA Manufacturing Market: Overview

Viral vectors are modified viruses used for delivering genetic materials to cells so that they can be manipulated for therapeutic purposes. They prevent new genes from degrading by delivering gene castle to targeted cells, and hence, the targeted cells use new genes to perform their required functions. Plasmid DNA genes are used as a tool for cloning, transferring, and manipulating genes. Some prominent qualities of plasmids include ease of working, self-replicating, and stability. These vectors were primarily used for understanding gene function and investigating RNAs and promoters, among other genetic materials.

Viral Vectors and Plasmid DNA Manufacturing Market: Segmentation

The study provides a decisive view of the viral vectors and plasmid DNA manufacturing market by segmenting the market based on product type, application, end-user, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

By product type, the market is segmented into viral vectors and plasmid. The viral vectors are further segmented into a retrovirus, lentiviruses, adenoviruses, adeno-associated viruses, and others. The plasmid segment includes DNA conjugative plasmids and non-conjugative plasmids.

By application, the market for viral vectors and plasmid DNA manufacturing is segmented into gene and cancer therapies, viral infections, immunotherapy, formulation development, and others.

By end-user, the market is segmented into biotechnology companies, research institutes, hospitals, and others.

Viral Vectors and Plasmid DNA Manufacturing Market: Report Scope

Viral Vectors and Plasmid DNA Manufacturing Market: Regional Analysis

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further division into major countries including the U.S., Rest of North America, UK, Germany, France, Italy, Spain, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, Brazil, Rest of Latin America, GCC Countries, South Africa, and Rest of the Middle East and Africa. This segmentation includes the demand for viral vectors and plasmid DNA manufacturing market based on individual product type, application, and end-user in all the regions and countries.

Viral Vectors and Plasmid DNA Manufacturing Market: Competitive Space

• Vigene Biosciences Inc.
• Lonza
• FinVector Vision Therapies
• Kaneka Corporation (Eurogentec)
• VGXI Inc.
• VIROVEK
• SIRION Biotech GmbH
• Cobra Biologics
• Novasep
• FUJIFILM Diosynth Biotechnologies Inc.
• Spark Therapeutics Inc.
• Genzyme Corporation
• ALDEVRON
• Brammer Bio
• Oxford Gene Technology
• General Electric Company (GE Healthcare)
• Among Others

The global viral vectors and plasmid DNA manufacturing market is segmented as follows:

By Product Type 

• Viral Vectors
  • Retrovirus
  • Lentiviruses
  • Adenoviruses
  • Adeno-Associated Viruses
  • Others
• Plasmids
  • DNA Conjugative Plasmids
  • Non-Conjugative Plasmids

By Application 

• Gene and Cancer Therapies
• Viral Infections
• Immunotherapy 
• Formulation Development
• Others

By End-User 

• Biopharmaceutical Companies
• Research Institutes
• Others?

By Region

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa